University Hospital Rangueil
Welcome,         Profile    Billing    Logout  
 10 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GUERCI, Bruno
REALIST, NCT03648554: Researching an Effect of GLP-1 Agonist on Liver STeatosis

Not yet recruiting
4
93
Europe
dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring
Central Hospital, Nancy, France, Eli Lilly and Company
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
09/23
03/24
ISLET CHIP, NCT03067324: Quality Control of Pancreatic Islet Intended to Islet Graft Cells Intended to Stabilot Islet Graft Protocol

Recruiting
N/A
40
Europe
University Hospital, Grenoble, University Hospital, Bordeaux
Pancreatic Islet Quality Control
12/20
07/21
RADIANT, NCT05923827: Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

Active, not recruiting
N/A
200
Europe
Omnipod 5 System
Insulet Corporation
Diabetes Mellitus, Type 1
08/24
08/25
GLUCOGEN, NCT06570278: Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical Diabetes

Recruiting
N/A
1020
Europe
WGS coupled with MCM
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Rennes University Hospital, Central Hospital, Nancy, France, Nantes University Hospital, Imagine Institute, APHP, Hospices Civils de Lyon, Université Lumière Lyon 2, Toulouse University Hospital
Diabetes Mellitus
11/31
11/34
PRO-DIAB-1, NCT06050642: Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.

Recruiting
N/A
420
Europe
enhanced care model provided by Timkl, a home support provider
timkl, Sanoia
Diabetes Mellitus, Type 1
05/25
05/25
SULTAN, Ariane
SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide

Completed
4
282
Europe, US, RoW
Tirzepatide, LY3298176, Dulaglutide, LY2189265
Eli Lilly and Company
Type 2 Diabetes
07/24
08/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
CHRONOS-2, NCT05074147: Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis

Not yet recruiting
3
280
Europe
Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks
Tourcoing Hospital
Osteomyelitis - Foot
11/24
11/26
Elodie Cohort, NCT03755323: Establishment of a Database of Patients Suffering From Obesity With a Medical Treatment

Recruiting
N/A
5000
Europe
University Hospital, Montpellier
BMI Greater Than 30
12/22
12/22
ACTIDIANE, NCT03184662: Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes

Recruiting
N/A
300
Europe
HIPA, Counseling PA
Poitiers University Hospital, University Hospital, Bordeaux, University Hospital, Clermont-Ferrand, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Universitaire de Besancon, Hopital Lariboisière, Bichat Hospital, Centre Hospitalier Sud Francilien, University Hospital, Lille, Centre Hospitalier Universitaire de Nice, University Hospital, Caen, University Hospital, Toulouse, University Hospital, Tours, Nantes University Hospital, Groupe Hospitalier Pitie-Salpetriere, Hospices Civils de Lyon, University Hospital, Montpellier, University Hospital, Strasbourg, Central Hospital, Nancy, France, HOSPITAL, CHARTRES, University of Liege
Type2 Diabetes, Diabetic Kidney Disease
09/23
12/23
CHEK BAC, NCT03964571: Human and Bacterial Protease Activity As Prognostic Tool of Foot Infections in Diabetic Patients

Completed
N/A
61
Europe
WOUNDCHEK
Centre Hospitalier Universitaire de Nīmes
Diabetic Foot Infection
03/24
12/24
CHARQUAM, NCT05491577: Factors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot

Recruiting
N/A
150
Europe
Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire
Centre Hospitalier Universitaire de Nīmes
Charcot Joint of Foot, Osteoarthropathy
07/27
01/28
GLUCOGEN, NCT06570278: Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical Diabetes

Recruiting
N/A
1020
Europe
WGS coupled with MCM
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Rennes University Hospital, Central Hospital, Nancy, France, Nantes University Hospital, Imagine Institute, APHP, Hospices Civils de Lyon, Université Lumière Lyon 2, Toulouse University Hospital
Diabetes Mellitus
11/31
11/34
FREEDIA, NCT05676593: Interest of FSL 2 in Recently Diagnosed Type 2 Diabetic Patients

Recruiting
N/A
40
Europe
Freestyle Libre 2, Therapeutic education
University Hospital, Montpellier
Endocrinology, Type 2 Diabetes
11/24
12/24
Diapepsy, NCT03323281: Neuropsychiatric Factors

Recruiting
N/A
266
Europe
Neuropsychological assessments
University Hospital, Montpellier, Inserm U1061 : Neuropsychiatry
Diabetes
12/24
06/25
FREESCA, NCT06014112: Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

Recruiting
N/A
850
Europe
Freestyle Libre Pro iQ
University Hospital, Montpellier
Acute Coronary Syndrome, Continuous Glucose Measurement, Glycemic Variability, Cardiovascular Event
05/26
05/26
PDF, NCT04533152: Prognostic Determinants in Patients With Diabetic Foot Ulcer.

Recruiting
N/A
1000
Europe, RoW
University Hospital, Bordeaux, Fondation Francophone pour la Recherche sur le Diabete
Diabetic Foot Ulcer
11/29
11/29

Download Options